Northwest Biotherapeutics Inc., of Bethesda, Md., inked definitive agreements with current institutional investors for a registered direct offering with gross proceeds of up to approximately $27.6 million and will exercise in full an overallotment option. The company will immediately sell about 5.88 million shares of common stock at a purchase price of $1.70 per share resulting in gross proceeds to the company of $10 million.